Treatment of Endocrine Gastroenteropancreatic Tumors with Somatostatin Analogues

Print
Published on Wednesday, 15 June 2016

Abstract

Somatostatin is a hormone that regulates the function of several exocrine and endocrine glands.

The peptide mediates its actions via five different receptors.

These proteins are expressed in a tissue-specific manner.

Somatostatin receptors are also present in neuroendocrine gastroenteropancreatic tumors.

Two long-acting somatostatin analogues, octreotide and lanreotide, are recognized by the receptor subtypes 2 and 5.

Excessive hormone secretion in carcinoid syndrome can be controlled by these drugs.

In addition, at least a subgroup of patients with carcinoid syndromes respond with delayed tumor growth during octreotide therapy.

In the future, the availability of the somatostatin receptor cDNAs will allow the development of specific and even more potent receptor analogues.

 

 

About this publication.

 

See also:

- Somatostatin in oncology, the overlooked evidences;

- The Di Bella Method Increases by the 30% the survival rate for Pancreas tumors and for this reason should be proposed as first line therapy for this type of cancer.